FromBio Q1 26 Operating Loss 3.3B Won, Debt Ratio Rises to 171%

Consolidated Q1 2026 revenue: 19.2 billion won (+3.6% YoY), operating loss 3.3 billion won
Net loss 3.7 billion won, EPS loss 128 won
Debt ratio 170.57%, up 21%p from year-end 2025 (149.61%)
Subsidiary FromBio Cosmetics continues capital impairment (equity -7.0 billion won)
Cash and equivalents 1.5 billion won, short-term borrowings 32.6 billion won - financial burden
Pending lawsuit for damages of 3.96 billion won (plaintiff: company)
No share buyback/cancellation or dividend plan
Exemption from designated management item for revenue and losses (grace period until 2025)